Combining Everolimus and 177Lu-DOTATATE for treating refractory meningioma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of combining Everolimus with 177Lu-DOTATATE in patients with grades 2 and 3 refractory meningioma, which are tumors that do not respond to standard treatments like surgery and radiotherapy. The study aims to evaluate the progression-free survival rate at six months, with a target of exceeding 30%, as recommended by the European Response Assessment in Neuro-Oncology group. Eligible participants must be adults under 80 years old with confirmed histology and specific imaging results indicating tumor progression. The trial is conducted at the Central Hospital in Nancy, France.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patient \< 80 years old, who received a complete comprehensive briefing about the trial and signed the informed consent
* Eligible patient for compassional access program (National Multidisciplinary Neuro-Oncology board to Lutathera ® traitement
* WHO performance status ≤ 3
* Patient with grade 2 and 3 meningioma, substantiated by histology, not amenable to surgery or radiotherapy, with clinical or radiological progression
* Clinical deterioration or at least 10% of tumor growth rate, defined as the product of the two largest diameters of the target lesion within 6 months
* Expressing somatostatin receptors as determined by 68Ga-DOTATOC PET (lesion uptake ≥ liver uptake and/or 1.7 fold SUVpeak of the controlateral meninges).
* Patient that underwent a brain MRI and 68Ga-DOTATOC PET within the last 2 months.
* Effective contraception required for women of childbearing age.
* Patient with social security cover.

Exclusion Criteria:

* Hypersensitivity to everolimus.
* Contraindication to 177Lu-DOTATATE: renal failure GFR\<40 mL/min/1.73m2 (calculated by the CKD-Epi Formula), hepatic failure total bilirubin \>3N, heart failure NYHA III or IV.

Patients should not take the following treatments:

* Other rapamycin derivatives (sirolimus, temsirolimus, deforolimus).
* Other immunosuppressants
* Co-administration with potent inhibitors and inducers of CYP3A4 and/or the multidrug efflux pump P-glycoprotein (PgP) : Ketoconazole , itraconazole, posaconazole, voriconazole, telithromycin, clarithromycin, Nefazodone, Ritonavir, atazanavir, saquinavir, darunavir, indinavir, nelfinavir.
* If everolimus is taken with orally administered CYP3A4 substrates with a narrow therapeutic index (e.g. pimozide, terfenadine, astemizole, cisapride, quinidine or ergot alkaloid derivatives), the patient should be monitored for undesirable effects described in the product information of the orally administered CYP3A4 substrate.
* Contraindication to MRI or 68Ga-DOTATOC PET/CT.
* Person referred to and L. 3212-1 and L. 3213-1 (psychiatric care).
* Women of childbearing age without effective contraception
* Patient unable to attend follow-ups over a 12-month period.
* Patients who participate in an interventional clinical research trial for the duration of the ELUMEN study.
* Individuals referred to in Articles 10, 31, 32, 33 and 34 of Regulation (EU) No 536/2014.
* Pregnant woman, birthing or breastfeeding mother
* Minor (not emancipated)
* Adult subject to a legal protection measure (such as guardianship, conservatorship)
* Adult who is unable to give consent

Where it's running

• Nancy Hospital
  Vandœuvre-lès-Nancy, France Recruiting
• CHRU of Nancy
  Vandœuvre-lès-Nancy, Grand Est, France Not yet recruiting

Study contacts

• Study coordinator: Antoine VERGER, MD,PhD
• Email: a.verger@chru-nancy.fr
• Phone: 0383155567

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combination therapy with IN10018 and dalpiciclib for progressive meningioma

  This phase 1 study tests whether taking IN10018 with dalpiciclib is safe and tolerable in adults with growing meningiomas to see if the combo can help control the tumor.

  Recruiting Phase 1 Capital Medical University · Beijing, Beijing Municipality and 1 other locations · NCT07652762

• JZP3507 (ONC206) for recurrent Grade 2/3 meningioma

  A pill-based therapy (JZP3507) is being tested to see if it can help adults with recurrent grade 2 or 3 meningioma who have not benefited from standard treatments.

  Recruiting at 6 sites Phase 2 Jazz Pharmaceuticals · San Francisco, California and 7 other locations · NCT07533942

• Panitumumab-IRDye800 for guiding brain tumor surgery

  A tiny dose of panitumumab-IRDye800 is tested to see if it helps visualize brain tumors during surgery in adults.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07493447

• Zanzalintinib for recurrent or progressive meningioma

  This trial tests whether zanzalintinib can help people whose meningioma has come back or kept growing after standard treatments.

  Recruiting at 20 sites Phase 2 Exelixis · Birmingham, Alabama and 19 other locations · NCT07428616

• Meningioma: How social factors and personal risks relate to health outcomes

  This study tests whether social and personal risk factors help explain differences in health outcomes for adults with meningioma.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07418775

• Skin closure after brain tumor surgery: running absorbable versus interrupted non-absorbable sutures

  This will test whether absorbable running intradermal sutures or non-absorbable interrupted transdermal sutures produce better wound healing after craniotomy in adults with supratentorial brain tumors.

  Recruiting Medical University of Warsaw · Warsaw, Masovian Voivodeship · NCT07413796

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.